Stoke Therapeutics (NASDAQ:STOK) Trading Down 3.5%

Stoke Therapeutics, Inc. (NASDAQ:STOK) was down 3.5% during trading on Tuesday . The stock traded as low as $13.30 and last traded at $13.38. Approximately 107,953 shares were traded during trading, a decline of 88% from the average daily volume of 930,787 shares. The stock had previously closed at $13.87.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on STOK shares. Wedbush boosted their price objective on Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Friday. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. Canaccord Genuity Group decreased their price target on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $20.57.

Stoke Therapeutics Stock Performance

The stock has a market cap of $672.87 million, a P/E ratio of -5.41 and a beta of 0.87. The business has a 50 day simple moving average of $13.82 and a 200-day simple moving average of $9.45.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $3.33 million. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.30% of the stock is currently owned by insiders.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its stake in Stoke Therapeutics by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock worth $425,000 after acquiring an additional 1,642 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after acquiring an additional 6,636 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics in the 1st quarter worth about $141,000. Sherbrooke Park Advisers LLC bought a new position in Stoke Therapeutics in the 3rd quarter worth about $48,000. Finally, Los Angeles Capital Management LLC increased its stake in Stoke Therapeutics by 30.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 62,257 shares of the company’s stock worth $327,000 after acquiring an additional 14,510 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.